stockportfolio.pro
Stocks / CLDX vs PBH
CLDX vs PBH
Celldex Therapeutics, Inc. and Prestige Consumer Healthcare Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Celldex Therapeutics, Inc. (CLDX) | Prestige Consumer Healthcare Inc. (PBH) | |
|---|---|---|
| Market cap | $2.3B | $2.3B |
| Revenue (latest FY) | $1.54M | $1.09B |
| Net income (latest FY) | $-258.76M | $190.30M |
| Revenue growth (5y CAGR) | -26.9% | 2.9% |
| Net margin | -16748.0% | 17.5% |
| Return on equity | -49.1% | 10.1% |
| P/E ratio | — | 12.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 8 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CLDX — free Open PBH — freeFrequently asked questions
Which is bigger, CLDX or PBH?
Celldex Therapeutics, Inc. is larger by market capitalization — $2.3B versus $2.3B.
Which grows faster, CLDX or PBH?
Over the last five fiscal years, Prestige Consumer Healthcare Inc. grew revenue faster — 2.9%/yr versus -26.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.